Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6020606 | Journal of Neuroimmunology | 2013 | 4 Pages |
Abstract
Vedolizumab, a gut-homing α4β7 integrin antagonist, has demonstrated efficacy in ulcerative colitis and Crohn's disease. Development of progressive multifocal leukoencephalopathy, a serious brain infection associated with natalizumab (an α4β7 and α4β1 integrin antagonist), has raised concern that vedolizumab may convey a similar risk. Natalizumab is believed to impair central nervous system immune surveillance by affecting cerebrospinal fluid (CSF) lymphocyte counts and the CD4:CD8 ratio. To determine if vedolizumab elicits similar effects, we examined CSF of healthy volunteers by flow cytometry for T-lymphocyte surface markers 5 weeks after administration of intravenous vedolizumab 450 mg. No significant changes were observed in CSF T-lymphocyte populations.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Catherine Milch, Tim Wyant, Jing Xu, Asit Parikh, Whitney Kent, Irving Fox, Joseph Berger,